Related Experiment Video
Updated: Nov 2, 2025
03:40
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
855
Rupatadine Oral Solution Titration by Body Weight in Paediatric Patients Suffering from Allergic Rhinitis: A
Eva Santamaria1,2, Iñaki Izquierdo2, Marta Valle1,3
1Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain.
Clinical Pharmacology : Advances and Applications
|June 17, 2021
Summary
Rupatadine pharmacokinetics in children aged 2-11 years shows weight-dependent clearance, not age-dependent. Weight-based dosing ensures consistent exposure, similar to adult doses, for allergic rhinitis and chronic urticaria treatment.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Drug Metabolism
Background:
- Second-generation antihistamine dosing in children often relies on adult data extrapolation.
- Allergic rhinitis (AR) and chronic urticaria are common pediatric conditions treated with antihistamines.
- Understanding rupatadine pharmacokinetics (PK) in children is crucial for optimized dosing.
Purpose of the Study:
- To develop a population pharmacokinetic (PK) model for rupatadine in children aged 2-11 years.
- To calculate non-compartmental PK parameters for pediatric age groups (2-5 and 6-11 years).
- To inform weight-based dosing strategies for rupatadine in pediatric populations.
Main Methods:
- Pooled data from two PK studies involving rupatadine oral solution in children.
- Developed a simultaneous population PK model using data from 51 children (2-11 years old).
- Simulated steady-state plasma concentrations and calculated PK parameters using Bayesian estimates.
Main Results:
- A two-compartment model with weight-dependent clearance best described rupatadine PK in children.
- Plasma clearance showed a linear dependence on body weight.
- Key PK parameters (Cmax, AUC0-24h, t1/2) were calculated for 2-5 and 6-11 year old groups.
Conclusions:
- Rupatadine PK in children (2-11 years) is influenced by body weight, not chronological age.
- A weight-based dosing strategy (2.5 mL for 10-25 kg, 5 mL for ≥25 kg) ensures comparable exposure.
- This dosing provides similar rupatadine exposure in children as the 10 mg tablet dose in adults.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
55
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
55
01:29Drug Dosing: Infants and Children
65
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
65
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
69
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
69
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
49
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
49
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
48
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
48
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
40
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
40